[Once upon a time the hepatotoxicity…].

The liver ensures a large part of xenobiotics metabolism thanks to its sizeable enzymatic equipment, its anatomical localization and its abundant vascularization. However, these various characteristics also make it a privileged target for toxic compounds, particularly in the case of a toxic metabolism. Xenobiotics-induced hepatotoxicity is a major cause of liver damage and a real challenge for clinicians, pharmaceutical industry, and health agencies. Intrinsic, i.e. predictable and reproducible hepatotoxicities occurring at threshold doses are distinguished from idiosyncratic hepatotoxicities, occurring in an unpredictable manner in people with individual susceptibilities. Among them, idiosyncratic immune-mediated hepatotoxicity pathophysiology is still unclear. However, the development of tools to improve the prediction and understanding of these disorders may open avenues to the identification of risk factors and new mechanisms of toxicity.

[1]  P. Watkins,et al.  Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. , 2020, Journal of medicinal chemistry.

[2]  A. Gerbes,et al.  Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug‐Induced Liver Injury , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  J. Uetrecht,et al.  Editor’s Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  Robert Preissner,et al.  Computational prediction of immune cell cytotoxicity. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[5]  C. Goldring,et al.  Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  J. Uetrecht,et al.  Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes. , 2017, Chemical research in toxicology.

[7]  Michael Merz,et al.  Drug-induced liver injury: recent advances in diagnosis and risk assessment , 2017, Gut.

[8]  D. Kleiner.  The histopathological evaluation of drug‐induced liver injury , 2017, Histopathology.

[9]  K. Tartaro,et al.  Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response , 2017, Journal of immunotoxicology.

[10]  Andrew R. Jones,et al.  A web resource for mining HLA associations with adverse drug reactions: HLA-ADR , 2016, Database J. Biol. Databases Curation.

[11]  Akira Nakajima,et al.  A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. , 2016, Toxicology letters.

[12]  Georg Damm,et al.  Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI , 2015, Mediators of inflammation.

[13]  D. Naisbitt,et al.  Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury , 2015, Allergy, asthma & immunology research.

[14]  A. Gerbes,et al.  Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury , 2015, Gut.

[15]  S. Thung,et al.  Histopathologic manifestations of drug-induced hepatotoxicity. , 2013, Clinics in liver disease.

[16]  Weida Tong,et al.  High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury , 2013, Hepatology.

[17]  S. Olafsson,et al.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. , 2013, Gastroenterology.

[18]  Neil Kaplowitz,et al.  Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. , 2013, Trends in pharmacological sciences.

[19]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[20]  Mitchell R. McGill,et al.  Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity , 2012, Drug metabolism reviews.

[21]  K. King,et al.  HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of Clinical Oncology.

[22]  D. Larrey.  Foie, médicaments et agents chimiques , 2009 .

[23]  J. Uetrecht,et al.  Immunoallergic Drug-Induced Liver Injury in Humans , 2009, Seminars in liver disease.

[24]  Ignazio Grattagliano,et al.  Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity , 2009, Current medicinal chemistry.

[25]  B. Mégarbane,et al.  Foie toxique : mécanismes lésionnels et thérapeutiques pharmacologiques spécifiques , 2007 .

[26]  N. Kaplowitz,et al.  c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. , 2006, Gastroenterology.

[27]  J. Brok,et al.  Interventions for paracetamol (acetaminophen) overdose. , 2006, The Cochrane database of systematic reviews.

[28]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[29]  G. Shenfield,et al.  Clinical implications of changes in hepatic drug metabolism in older people , 2005, Therapeutics and clinical risk management.

[30]  N. Kaplowitz,et al.  Clinical Perspectives on Xenobiotic‐Induced Hepatotoxicity , 2004, Drug metabolism reviews.

[31]  E. Christensen,et al.  Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose , 2002, Alimentary pharmacology & therapeutics.

[32]  G. McDonald,et al.  Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.

[33]  P. Balladur,et al.  Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. , 2001, Chemical research in toxicology.

[34]  A. Rašković,et al.  The activity of liver oxidative enzymes after single and multiple grapefruit juice ingestion. , 1999, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[35]  P. Nicotera,et al.  Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.

[36]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver disease. , 1995, Gastroenterology clinics of North America.

[37]  C. Bénichou.  Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[38]  N. Kaplowitz,et al.  Halothane-lnduced Hepatic Disease , 1981, Seminars in liver disease.

[39]  J. Talwalkar,et al.  Drug-induced liver injury. , 2014, Mayo Clinic proceedings.

[40]  R. Verbeeck,et al.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction , 2008, European Journal of Clinical Pharmacology.

[41]  N. Kaplowitz.  Biochemical and Cellular Mechanisms of Toxic Liver Injury , 2002, Seminars in liver disease.

[42]  K. Jaskiewicz,et al.  Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. , 1996, Journal of toxicology. Clinical toxicology.